Hims & Hers Health (NYSE:HIMS) Trading Down 0.2%

Hims & Hers Health, Inc. (NYSE:HIMS) traded down 0.2% during trading on Friday . The company traded as low as $19.59 and last traded at $19.97. 3,175,613 shares were traded during mid-day trading, a decline of 57% from the average session volume of 7,364,958 shares. The stock had previously closed at $20.02.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Jefferies Financial Group upped their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday. TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Citigroup cut shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their target price for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Finally, Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price on the stock. Seven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Hims & Hers Health Price Performance

The stock’s 50 day moving average is $17.59 and its two-hundred day moving average is $13.52. The stock has a market capitalization of $4.34 billion, a PE ratio of -2,019.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,546 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66. Following the sale, the chief financial officer now directly owns 177,449 shares in the company, valued at $3,941,142.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total value of $2,827,653.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 11,546 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66. Following the completion of the transaction, the chief financial officer now owns 177,449 shares in the company, valued at $3,941,142.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 962,791 shares of company stock worth $16,930,725. Company insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in HIMS. Forerunner Ventures Management LLC purchased a new position in Hims & Hers Health in the fourth quarter valued at approximately $86,836,000. Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the period. M&G Plc acquired a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $8,232,000. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after acquiring an additional 428,671 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Hims & Hers Health by 39.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock valued at $8,006,000 after acquiring an additional 357,590 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.